Tirzepatide drives greater, faster weight loss than semaglutide in real-world cohort
Background
The management of obesity and type 2 diabetes has been revolutionized by glucagon-like peptide-1 receptor agonists (GLP-1RAs). However, significant variability in individual weight-loss response and adverse event profiles remains a challenge, limiting optimal patient selection and personalized treatment strategies. Understanding these real-world differences between leading GLP-1RAs like semaglutide and the dual GLP-1R/GIPR agonist tirzepatide is crucial for refining clinical guidelines and improving patient outcomes.
Study Design
Researchers conducted a retrospective cohort study using de-identified electronic health records. They performed 1:1 propensity matching on age, sex, type 2 diabetes status, baseline BMI, weight, index year, and follow-up duration. The matched cohorts included 10,339 tirzepatide-treated and 10,339 semaglutide-treated patients. Patients were categorized by maximum weight loss over 2 years into five response groups. Adverse events were identified through AI-enabled curation of clinical notes, and pre- to post-treatment disease prevalence changes were compared.
Results
Patients treated with tirzepatide experienced significantly greater weight loss than those treated with semaglutide, with a mean reduction of 14.7% versus 10.8% respectively (P < 0.001). High-response rates, defined as ≥15% weight loss in year 1, were nearly doubled with tirzepatide (42.6%) compared to semaglutide (21.6%; P < 0.001). This was accompanied by a faster monthly weight-loss velocity for tirzepatide (2.54%) versus semaglutide (2.18%). AI-enabled curation of clinical notes also revealed that tirzepatide was associated with a lower prevalence of both gastrointestinal and systemic adverse events.
Women were more represented among high responders than the minimal weight-loss group (<5% weight loss) for both drugs. Furthermore, White patients were more frequently high responders, while Black and Hispanic patients were more represented in the minimal weight-loss group, highlighting significant demographic variations in treatment outcomes.
Key Findings
- Tirzepatide led to 14.7% mean weight loss vs. 10.8% for semaglutide (P < 0.001).
- High-response rates (≥15% weight loss in year 1) were 42.6% for tirzepatide vs. 21.6% for semaglutide (P < 0.001).
- Tirzepatide showed faster monthly weight-loss velocity (2.54% vs. 2.18%).
- Tirzepatide was associated with lower prevalence of gastrointestinal and systemic adverse events.
- Demographic disparities observed: women and White patients were more often high responders.
Why It Matters
This large real-world study provides compelling evidence that tirzepatide offers superior weight loss efficacy and potentially better tolerability compared to semaglutide in a diverse patient population. For clinicians and individuals managing obesity or type 2 diabetes, this data supports considering tirzepatide as a potentially more effective option for achieving substantial weight reduction. The observed demographic disparities underscore the critical need for future clinical trials and routine care decisions to incorporate diverse patient populations, ensuring equitable access to and efficacy of incretin therapies. This insight could inform personalized treatment strategies, guiding choices between GLP-1RAs based on expected efficacy and tolerability profiles.
tirzepatide
semaglutide
obesity
weight loss
type 2 diabetes
real-world data